anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Inadequately managed postoperative pain remains a common issue. Examining factors like pain sensitivity, pain catastrophizing, and pain self-efficacy can help improve postoperative pain management. While these factors have been identified as potential predictors of acute postoperative pain, their effects have been inconsistent. Few studies have explored the interactions between these factors.
AIM: To investigate the influence of preoperative pain sensitivity, pain catastrophizing, and pain self-efficacy on acute postoperative pain in abdominal surgery patients and to determine the mediating roles of pain catastrophizing and pain self-efficacy in the relationship between pain sensitivity and acute postoperative pain, as per the gate control theory.
METHODS: A total of 246 patients were enrolled in this study. General information was collected before surgery, and the Pain Sensitivity Questionnaire (PSQ), Pain Catastrophizing Scale (PCS), and Pain Self-Efficacy Questionnaire (PSEQ) were administered. After surgery, patients' average pain scores over the 24 hours were reported using the Numerical Rating Scale (NRS). Correlation analyses and a structural equation model were used to examine the relationships among these variables.
RESULTS: NRS scores over 3 during the 24 hours post-surgery were reported by 21.54% of patients. Postoperative acute pain was found to be associated with pain sensitivity (rs = 0.463, p < .001), pain catastrophizing (rs = 0.328, p < .001), and pain self-efficacy (rs = -0.558, p < .001). A direct effect on postoperative acute pain was exerted by pain sensitivity (effect = 0.250, p = .001), along with indirect effects through: (A) pain catastrophizing (effect = 0.028, p = .001); (B) pain self-efficacy (effect = 0.132, p = .001); and (C) the chain mediation of pain self-efficacy and pain catastrophizing (effect = 0.021, p = .008).
CONCLUSIONS: The severity of postoperative acute pain can be predicted by pain self-efficacy and pain catastrophizing, and the connection between moderate pain sensitivity and postoperative acute pain severity is mediated by them. Therefore, intervention programs aimed at boosting pain self-efficacy and reducing pain catastrophizing can enhance postoperative pain outcomes for abdominal surgery patients.
A sustained-release multiple unit formulation containing a galantamine hydrobromide is provided to release the galantamine hydrobromide by coating release control drug layer with control film of release. A sustained-release multiple unit formulation containing a galantamine hydrobromide comprises: a pharmaceutical inactive multiple unit core; a release control drug layer of water-insoluble polymer; and a release control film. The multiple unit core comprises a white sugar sphere or white sugar containing white sugar and corn starch. The release control drug layer comprises the galantamine hydrobromide and is applied on the surface of the core. The water-insoluble polymer is ethylcellulose or aqueous dispersion of ethylcellulose. The release control film is applied on the surface of the layer and comprises water-insoluble polymer or water-soluble polymer.
A COVID-19 confirmed case is a patient with an acute respiratory illness and RT-PCR confirmation of SARS-CoV-2 infection (i.e. any positive RT-PCR results obtained prior to admission or after enrolment in the study). In case the patient has any inconsistent RT-PCR results (e.g. a positive followed by a negative or a negative followed by a positive result), he/s he/she will be considered as a COVID-19 confirmed case if he/she has at least one positive result during his/her illness under consideration.
A system for providing anonymous access to health information may include an interface, a memory and a web portal. The interface may be operative to receive a test result of a biological sample of an individual and a unique identifier associated with the test result. The individual may not be identifiable by the unique identifier. The memory may be operative to store a record in a database. The record may include the test result and the unique identifier associated with the test result. The web portal may be coupled with the database and may be operative to receive the unique identifier from a user. The web portal may retrieve the record comprising of the unique identifier, and display the test result stored in the record to the user.
PURPOSE: Lipid-lowering therapy is integral in acute ischemic stroke (AIS), yet the connection between lipid parameters and parenchymal hemorrhage (PH) after endovascular treatment (EVT) for AIS is not well-defined. This research aims to assess the association between various lipid parameters and the PH risk following EVT.
PATIENTS AND METHODS: We examined a database of patients who underwent EVT for AIS between September 2021 and May 2023 retrospectively. Traditional and non-traditional lipid parameters were documented. PH was identified on dual energy computed tomography images within 48 h. We employed logistic regression analysis and restricted cubic splines to examine the association between various lipid parameters and the risk of PH. The predictive capacity of the lipid parameters for PH was evaluated by comparing the area under the curve.
RESULTS: The study included 384 patients, 65 of whom (17.7%) developed PH. After adjusting for potential confounders, only triglyceride was associated with PH among the traditional lipid parameters, while all non-traditional lipid parameters were related to PH. Based on ROC curve, the ratio of remnant cholesterol to high-density lipoprotein cholesterol (RC/HDL-C) exhibited the highest predictive capability for PH. Furthermore, our analysis revealed a significant nonlinear correlation between triglyceride, non-high-density lipoprotein cholesterol, RC, RC/HDL-C and PH risk.
CONCLUSION: In assessing the risk of PH after EVT, non-traditional lipid parameters are often superior to traditional lipid parameters. It is recommended that routine evaluation of non-traditional lipid parameters could also be conducted in clinical practice as well.
Experimental group received ankle strategy exercises in addition to balance exercises for a period of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly). Ankle strategy exercises included raising and lowering heels and forefeet, heel to toe walking, stepping up and down and right and left and diagonal inclination of body during standing.
BACKGROUND: Metabolic syndrome (MetS) in adolescence is a risk factor for future cardiovascular disease. The chronic inflammation associated with MetS can be attenuated by the anti-inflammatory effect of polyphenols. We aimed to evaluate total urinary polyphenols as a biomarker of anti-inflammatory diets and their effect on MetS in adolescents.
METHODS: In this retrospective analysis of a longitudinal cohort study, the relationship between total polyphenol excretion (TPE) in urine, the inflammatory potential of the diet measured through the Children's Dietary Inflammatory Index (C-DII), and the presence of metabolic syndrome was evaluated. The study population consisted of adolescents enrolled in the SI! Program for Secondary Schools trial, who had completed all the study forms and provided urine samples at baseline and at the two-year follow-up. Multivariate linear regression and multinominal logistic regression models were generated to evaluate the relationship of changes in TPE with changes in the C-DII score and changes in MetS status, respectively. An analysis of the ROC curve was performed to assess the potential of TPE as a biomarker of an anti-inflammatory diet.
RESULTS: This study included 662 adolescents, 51.2% were males, and 48.8% were females, with a mean age of 12 (0.38) years at baseline. The relationship between changes in TPE and changes in the C-DII score was stratified by sex with a p-value <0.001 for the interaction. TPE and C-DII were inversely associated in males (-0.13 mg GAE/g creatinine [-0.26; -0.01] per 1-SD increase, p-value = 0.037). In addition, an increase in changes in TPE levels were associated with a reversal in MetS status in all adolescents (1.30 [1.27; 1.34] per 1-SD increase, p-value<0.001). The ROC curve showed that urinary TPE levels can predict dietary inflammatory potential with an AUC = 0.793 (0.725; 0.863) in males.
CONCLUSION: Polyphenols excreted in urine are a potential biomarker of anti-inflammatory diets in males and are associated with a reversal of MetS status in adolescents.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, Identifier: NCT03504059, https://clinicaltrials.gov/study/NCT03504059.
The invention discloses a seaweed protein healthcare capsule with a blood sugar-reducing function. The seaweed protein healthcare capsule with a blood sugar-reducing function is scientifically prepared by compounding seaweed protein and Chinese herbal medicine raw materials. Preferably, the seaweed protein healthcare capsule is prepared from the following raw materials in parts by weight: 30-40 parts of seaweed protein, 15-20 parts of astragalus roots, 15-18 parts of Chinese wolfberry fruits, 10-14 parts of kudzuvine roots, 8-10 parts of radix polygoni multiflori, 8-10 parts of licorices, 6-10 parts of prepared rhizoma rehmanniae, 4-8 parts of white atractylodes rhizome, 5-8 parts of rhizoma chuanxiong, 4-6 parts of radix polygalae, 4-6 parts of anemarrhena rhizome, 4-6 parts of Apocynum lancifolium Rus., 3-5 parts of dandelion herbs and 2-3 parts of Chinese caterpillar fungus. The preparation technology comprises the following steps of compounding according to the proportion, mixing, sterilizing and capsule filling. The seaweed protein healthcare capsule has the advantages that the seaweed protein and the Chinese herbal medicines are coordinated, so that the seaweed protein healthcare capsule has the effects of reducing blood sugar, replenishing Qi, tonifying body, strengthening the body resistance, consolidating the origin, resisting fatigue, prolonging life and the like. The seaweed protein healthcare capsule is safe, and is free of side effect, convenient to eat and good in market application prospect.
The invention relates to organic chemistry and chemico-pharmaceutical industry, in particular to a process for the preparation of substituted 3-heteryl-2H-chromen-2-imines and 2-N-arylimino derivatives thereof that are useful for bioactivity screening and can be used as laser dyes and luminescent indicators or artificial precursors thereof. The process is carried out by interaction of anthranil amides and thioanthranil amides, or 2-aminothiophene-3-caboxamides, or thiosemicarbazides with equimolar amount of 2-imino-2H-chromen-3-carbonitriles or 2-imino-2H-chromen-3-carbothiamides in acetic acid at a temperature of 25-80 °C for 20-30 min. with formation of precipitate followed by washing filtered precipitate with ethyl or isopropyl alcohol and drying. Semiproduct prepared is heated at a temperature of 135-150 °C in dimethylformamide medium for 15 min. – 3 hours with formation of precipitate which is filtered, washed with ethyl or isopropyl alcohol and dried. Corresponding 3-heteryl-2H-chromen-2-imine is prepared, this is added in equimolar amount to arylamine solution. The reaction is carried out in glacial acetic acid at a temperature of 60-80 °C for 20-30 min. with furher cooling the reaction mixture to room tempeprature. The precipitate formed is filtered, washed with ethyl or isopropyl alcohol, dried and crystallized from dimethylformamide. Corresponding 3-heteryl-2H-chromen-2-imine 2-N-arylimino derivative is prepared.
PURPOSE: A combination composition containing liposomic camptothecin and liposomic flouropyrimidines is provided to improve treatment effect for hyperproliferative diseases and tumor. CONSTITUTION: A combination composition for treating hyprproliferative diseases contains a liposome binding to soluble camptothecin and additional targeted anti-tumor agent. The targeted anti-tumor agent is an agent for suppressing angiogenesis or tyrosine kinase-mediated receptor activity inhibitor. An agent for suppressing angiogenesis is vascular endothelial growth factor(VEGF) inhibitor. The tyrosine kinase-mediated receptor inhibitor is epithelial growth factor receptor. A combination composition for treating hyperproliferative diseases contains fluoropyrimidine which stably binds to a first liposome, water-soluble camptothecin which stably binds to a second liposome and additional targeted anti-tumor agent.
The present disclosure discloses an application of scutellarein in the preparation of drugs for treating pancreatic cancer. According to the present disclosure, scutellarein is applied to the treatment of pancreatic cancer for the first time. The pancreatic cancer cell line PANC-l is chosen to evaluate the activity of scutellarein. The results show that scutellarein can signiﬁcantly inhibit the proliferation and colony formation of PANC-l cells. In the in Vivo experiment, BALB/c nude mice are inoculated with PANC-l cells, and treated with scutellarein by intraperitoneal injection. The results show that scutellarein can inhibit the growth of transplanted tumors in nude mice, and the tumor inhibition rate is signiﬁcantly different from that in the control group.
Astaxanthin (AST) is a natural marine carotenoid with a variety of biological activities. This study aimed to demonstrate the possible mechanisms by which AST improves skeletal muscle atrophy in cancer cachexia. In this study, the effects of different doses of AST (30 mg/kg b.w., 60 mg/kg b.w. and 120 mg/kg b.w.) on skeletal muscle functions were explored in mice with cancer cachexia. The results showed that AST (30, 60 and 120 mg/kg b.w.) could effectively protect cachexia mice from body weight and skeletal muscle loss. AST dose-dependently ameliorated the decrease in myofibres cross-sectional area and increased the expression of myosin heavy chain (MHC). AST treatment decreased both the serum and muscle level of IL-6 but not TNF-α in C26 tumor-bearing cachexia mice. Moreover, AST alleviated skeletal muscle atrophy by decreasing the expression of two muscle-specific E3 ligases MAFBx and MuRF-1. AST improved mitochondrial function by downregulating the levels of muscle Fis1, LC3B and Bax, upregulating the levels of muscle Mfn2 and Bcl-2. In conclusion, our study show that AST might be expected to be a nutritional supplement for cancer cachexia patients.
Several studies described how weight of prisoners may vary during incarceration. Taking or losing weight both have health consequences but are also a warning signal for several pathologies. Female prisoners are more likely getting fat, data are rare and contradictory about male prisoners. A single study was conducted in mainland France and including few men. Furthermore, Martinique is a department where the prevalence of overweight and diabetes in the general population are higher than the national average. Prisoners most often have socio-demographic featuring and morbidity different from the general population (more men, some over-represented age groups, addictive behaviors and more frequent mental health problems ...). Aspects nutritional information is less often documented. What about the weight variation of people held in Martinique? Is incarceration always accompanied by weight gain? What are factors associated with weight variation? This study aims to answer to those questions by including all men newly admit in the only martinican jail aged from 18 to 44 years and consenting. During admission medical consultation, prisoners will fill guided by the investigator doctor of self-questionnaires of the evaluation of the level of physical activity, assessment of nutritional intakes and psychological state before incarceration. Measurement of weight and other anthropometrics data will be done, investigator doctor will collect data about socio-economic featuring, medical history and treatment. Three months later, a research technician will interview included prisoners in their life place and guide them to fill new self-questionnaires of the evaluation of the level of physical activity, assessment of nutritional intakes and psychological state during incarceration. Measure weight and other anthropometrics data and collecting data about new treatment, stopping tobacco will be done during this interview.
About 35 patients with alopecia areata will Subject to fractional Erbium (Er-YAG) laser (Fotona Xs dynamics,Slovenia) with energy of 600 mj in short pulse mode (MSP) with spot size of 7 mm diameter, frequency of 3 Hz and pixel 3. Latanoprost( xalatan 0.005% ) is applied to the treated area for all participants.
BACKGROUND: Patients affected by polyneuropathy often report pain, paraesthesia and numbness and are at risk of having an increased propensity to fall with the corresponding complications. In case of persistent symptoms after all conservative and medical treatment options have been exhausted, a nerve decompression in the lower leg as described by Dellon can lead to an improvement of the discomfort for many patients. This article presents our long-term results with Dellon's operation.
METHODS: In this retrospective study, we included 33 patients with diabetic or idiopathic polyneuropathy in whom we performed Dellon's nerve decompression in the lower leg in the years 2011-2013. In 29 out of the 33 patients, we investigated the level of pain (according to the numeric rating scale NRS 0-10), paraesthesia, numbness, Hoffman-Tinel sign, and Semmes-Weinstein monofilaments three months postoperatively. 88 months postoperatively (range 78-111 months), we were able to contact 20 of the 33 patients with a questionnaire asking about their present pain level (NRS 0-10), satisfaction with the postoperative result (NRS 0-10, 0=most satisfied, 10=not satisfied at all) and whether the patients would recommend the surgical procedure to their friends or family.
RESULTS: 1. Significant pain reduction three months postoperatively, NRS 4.5 to 2.2, (p=0.000). 2. Significant reduction of paraesthesia three months postoperatively from 84.8 to 24.2% (p=0.000) 3. Significant reduction of numbness three months postoperatively from 97% to 39% (p=0.000). 4. Significant improvement of sensitivity three months postoperatively from 91% no sensitivity to 28% no sensitivity (p=0.000). 5. Significant improvement of Hoffmann-Tinel sign three months postoperatively from 76% to 13% (p=0.000). 88 months postoperatively, we saw a significant pain reduction from an average preoperative pain level of NRS 4.5 to a postoperative pain level of 2.7 (p=0.048). 88 months postoperatively, 65% of the patients would recommend the surgical procedure to their family and friends, and patient satisfaction was high (NRS 3,4).
CONCLUSION: Our long-term results show that Dellon's nerve decompression in the lower extremities leads to a marked, lasting pain reduction and a functional improvement.
Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
Our previous study found that miR-26a alleviates aldosterone-induced tubulointerstitial fibrosis (TIF). However, the effect of miR-26a on TIF in diabetic kidney disease (DKD) remains unclear. This study clarifies the role and possible mechanism of exogenous miR-26a in controlling the progression of TIF in DKD models. Firstly, we showed that miR-26a was markedly decreased in type 2 diabetic db/db mice and mouse tubular epithelial cells (mTECs) treated with high glucose (HG, 30 mM) using RT-qPCR. We then used adeno-associated virus carrying miR-26a and adenovirus miR-26a to enhance the expression of miR-26a in vivo and in vitro. Overexpressing miR-26a alleviated the TIF in db/db mice and the extracellular matrix (ECM) deposition in HG-stimulated mTECs. These protective effects were caused by reducing expression of protease-activated receptor 4 (PAR4), which involved in multiple pro-fibrotic pathways. The rescue of PAR4 expression reversed the anti-fibrosis activity of miR-26a. We conclude that miR-26a alleviates TIF in DKD models by directly targeting PAR4, which may provide a novel molecular strategy for DKD therapy.
The operative mortality is a key point of the risk-to-benefit ratio analysis before considering cardiac surgery. Operative risk evaluation in a single surgical center is a part of medical care quality assessment. It must be interpreted in the light of the local specificities, in particular the characteristics of the patients and the types of surgery. The local database results from a joint initiative of anesthesic, cardiology and cardiac surgery departements.Its purpose is to record in an exhaustive fashion all the interventions of cardiac surgery performed under extracorporeal circulation in adults at Bichat hospital.This database includes the preoperative characteristics of the patients, the type of surgery, the post-operative complications and the in-hospital mortality. The purpose of this observational study is to evaluate in-hospital morbidity and mortality according to the characteristics of the patients and the type of intervention. study population : inclusion criteria : patient 18 years or older with legal capacity, patients with non-objection to record his/her medical data during hospitalization. Methods: this is an observational prospective and monocentric study. The main objective is to report in-hospital mortality for all types of cardiac surgery performed in Bichat hospital . The secondary objectives are :1) to collect post-operative complications such as hemorrhagic or thromboembolic events or surgery site infections; 2) to analyze mortality rate and post-operative morbidities according to the type of surgery and the main patients' characteristics . 3) to calculate validated and currents risk score such as EuroSCORE I and II for each patient.
A hair straightening topical composition comprising transglutaminase and polylysine, which act to form a surface barrier film and moisture shield around human hair. The transglutaminase also contributes to hair straightening. The composition also comprises one or more additional hair straightening agents, other than TGase, that are capable of affecting secondary, tertiary and quaternary protein structures of human hair, preferably sodium metabisulfite and/or tourmaline. The invention includes compositions that may be washed out of the hair after straightening has occurred, and compositions that are intended to remain in the hair for additional or extended benefits. The invention includes methods of using a topical composition that is capable of affecting secondary, tertiary and quaternary protein structures of human hair. Testing indicates that the hair straightening is long term, occurs significantly faster than known commercial hair straightening compositions, and there is significantly less damage to hair compared to known heat and chemical treatments.